Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year's San Antonio Breast Cancer meeting. I'm Hope Rugo, professor of medicine at the University of California San Francisco's Comprehensive Cancer Center, and I'm joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco's Comprehensive Cancer Center. Thanks for joining me today.
So today, in our first discussion, we're going to talk about immunotherapy. This generated great interest at San Antonio and, of course, at all of the major meetings today that discussed breast cancer this year in 2020. I think we saw updates on immunotherapy that are potentially practice-changing at ASCO and ESMO Breast Cancer and ESMO, and now at San Antonio. Jo, do you want to start and talk a little bit about the update on KEYNOTE-355 and some of the other controversies that have arisen with the presentation of updated overall survival with IMpassion130, and then the very interesting and intriguing data from IMpassion131?